We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple Blood Test Detects Early Liver Cancer in At-Risk Patients

By LabMedica International staff writers
Posted on 08 Jul 2022
Print article
Image: HelioLiver is a simple blood test for liver cancer (Photo courtesy of Helio Genomics)
Image: HelioLiver is a simple blood test for liver cancer (Photo courtesy of Helio Genomics)

Half of all liver cancers are diagnosed at an early stage when the disease is still localized. Almost 90% of liver cancer is made up of hepatocellular carcinoma (HCC). Patients at risk for HCC include those with: pre-existing cirrhosis, chronic hepatitis B or hepatitis C, excessive alcohol use, and nonalcoholic fatty liver disease (NAFLD). Less-prevalent conditions, such as hereditary hemochromatosis, primary biliary cholangitis (PBC), and Wilson's disease, have also been associated with HCC development. Early detection of liver cancer significantly improves outcomes for patients, allowing for a higher survival rate, and more time to treat the disease. Now, a revolutionary new blood test can help detect HCC earlier, allowing at-risk patients access to more curative treatment options and improving outcomes overall.

The HelioLiver Test from Helio Genomics (Irvine, CA, USA) allows physicians to efficiently screen more patients with one simple, affordable blood test that integrates seamlessly with in-office patient care. By combining the results of cell-free DNA (cfDNA) methylation testing with data from protein tumor markers and other clinical information, the multi-analyte blood test delivers superior performance characteristics when compared to traditional blood tests for HCC. The HelioLiver Test is three times more sensitive than the current standard of care for early stage detection for small lesions.

HelioLiver requires only a simple blood draw that can be conducted during the same physician visit, instead of needing to schedule an additional appointment. The test is intended for surveillance of HCC in men and women age 21 and over who are designated to be at high-risk for HCC due to a diagnosis of liver cirrhosis. The HelioLiver test is not intended as a replacement for diagnostic biopsies or diagnostic imaging by contrast enhanced MRI or CT.

Related Links:
Helio Genomics 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.